SCHEMBL7708018

SCHEMBL7708018

CC1=C(N)Nc2cc(CN(Cc3ccc(Cl)cc3Cl)C(=O)OC(C)(C)C)ccc2O1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.33
ERCC4 Q92889 1/20 0.33
SLC6A2 P23975 3/20 0.33
SLC6A4 P31645 3/20 0.33
IDO1 P14902 2/20 0.33
TP53 P04637 4/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 2/20 0.33
HTT P42858 2/20 0.33
MAPT P10636 2/20 0.33
GLA P06280 1/20 0.33
XBP1 P17861 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SLC6A3 Q01959 1/20 0.33
ADCY8 P40145 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704988 0.91 HDAC3 (0.36) TP53ALDH1A1HTTMAPTNPSR1
SCHEMBL7704965 0.91 HDAC3 (0.36) TP53ALDH1A1HPGDHTTMAPT
SCHEMBL7704902 0.88 RIPK1 (0.37) SMN1; SMN2KDM4EHDAC3HDAC1HDAC2
SCHEMBL7711458 0.88 HDAC3 (0.33) SLC6A2SLC6A4HPGDSLC6A3SMN1; SMN2
SCHEMBL7713369 0.86 HDAC1 (0.34) TP53HSD17B10HDAC3HDAC1HDAC2
SCHEMBL7711366 0.85 HDAC1 (0.37) ALDH1A1SMN1; SMN2HDAC3HDAC1HDAC2
SCHEMBL7708189 0.85 HDAC3 (0.37) TP53ALDH1A1HPGDMAPTHSD17B10
SCHEMBL7704910 0.84 HDAC1 (0.45) ALDH1A1NPSR1HSD17B10SMN1; SMN2MEN1
SCHEMBL7710867 0.84 ALDH1A1 (0.38) TP53ALDH1A1HTTMAPTNPSR1
SCHEMBL7711307 0.84 ALDH1A1 (0.42) ALDH1A1HPGDMAPTNPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed